DK2044025T3 - Quinolinonderivater samt farmaceutiske sammensætninger deraf - Google Patents

Quinolinonderivater samt farmaceutiske sammensætninger deraf

Info

Publication number
DK2044025T3
DK2044025T3 DK07819899.1T DK07819899T DK2044025T3 DK 2044025 T3 DK2044025 T3 DK 2044025T3 DK 07819899 T DK07819899 T DK 07819899T DK 2044025 T3 DK2044025 T3 DK 2044025T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
quinolinone derivatives
quinolinone
derivatives
pharmaceutical
Prior art date
Application number
DK07819899.1T
Other languages
English (en)
Inventor
Stephanie Monnier
Jean-Louis Reber
Olivier Lohse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2044025T3 publication Critical patent/DK2044025T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK07819899.1T 2006-06-30 2007-07-02 Quinolinonderivater samt farmaceutiske sammensætninger deraf DK2044025T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK2044025T3 true DK2044025T3 (da) 2013-01-14

Family

ID=38610531

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07819899.1T DK2044025T3 (da) 2006-06-30 2007-07-02 Quinolinonderivater samt farmaceutiske sammensætninger deraf

Country Status (27)

Country Link
US (2) US8198450B2 (da)
EP (1) EP2044025B1 (da)
JP (1) JP5253392B2 (da)
KR (1) KR101402398B1 (da)
CN (1) CN101479245B (da)
AU (1) AU2007264946B2 (da)
BR (1) BRPI0713951B8 (da)
CA (1) CA2654801C (da)
CY (3) CY1113733T1 (da)
DK (1) DK2044025T3 (da)
ES (1) ES2396987T3 (da)
FR (2) FR20C1054I1 (da)
HK (1) HK1127597A1 (da)
HR (1) HRP20121074T1 (da)
HU (2) HUS2000043I1 (da)
IL (1) IL195796A (da)
LT (2) LTC2044025I2 (da)
MA (1) MA30540B1 (da)
MX (1) MX2008016542A (da)
MY (1) MY150468A (da)
NO (3) NO341709B1 (da)
NZ (1) NZ573292A (da)
PL (1) PL2044025T3 (da)
PT (1) PT2044025E (da)
SI (1) SI2044025T1 (da)
WO (1) WO2008000839A1 (da)
ZA (1) ZA200809948B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
BRPI0816278A2 (pt) * 2007-09-05 2015-09-22 Pfizer Ltd forma sal
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
KR102074543B1 (ko) 2013-03-14 2020-02-06 노파르티스 아게 분무-블렌딩을 통한 분무-건조 제제의 탈무정형화
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en) 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
BRPI0409198A (pt) * 2003-04-04 2006-05-02 Novartis Ag derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
PL1869049T3 (pl) 2005-03-21 2009-07-31 Lilly Co Eli Związki imidazopirydazyny
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
MY150468A (en) 2014-01-30
ZA200809948B (en) 2009-05-25
HUS2000053I1 (hu) 2020-12-28
NO2020044I1 (no) 2020-12-07
EP2044025B1 (en) 2012-10-03
BRPI0713951B8 (pt) 2021-05-25
IL195796A0 (en) 2009-09-01
IL195796A (en) 2016-03-31
HUS2000043I1 (hu) 2020-12-28
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
CA2654801A1 (en) 2008-01-03
CY2020041I1 (el) 2021-03-12
LTPA2020538I1 (lt) 2021-01-11
CY1113733T1 (el) 2016-06-22
MX2008016542A (es) 2009-01-19
CN101479245B (zh) 2013-05-22
ES2396987T3 (es) 2013-03-01
BRPI0713951A2 (pt) 2012-12-04
NZ573292A (en) 2011-03-31
JP2009541455A (ja) 2009-11-26
NO2020041I1 (no) 2020-11-23
BRPI0713951B1 (pt) 2019-08-13
LTPA2020535I1 (lt) 2020-12-28
FR20C1063I1 (fr) 2021-01-22
LTC2044025I2 (lt) 2022-10-10
PT2044025E (pt) 2012-12-17
US20120316142A1 (en) 2012-12-13
PL2044025T3 (pl) 2013-02-28
EP2044025A1 (en) 2009-04-08
NO341709B1 (no) 2018-01-02
SI2044025T1 (sl) 2013-01-31
NO20090312L (no) 2009-01-28
AU2007264946B2 (en) 2011-01-20
US20090325912A1 (en) 2009-12-31
MA30540B1 (fr) 2009-06-01
US8198450B2 (en) 2012-06-12
JP5253392B2 (ja) 2013-07-31
KR101402398B1 (ko) 2014-06-03
FR20C1054I1 (fr) 2020-12-25
CY2020038I1 (el) 2021-03-12
KR20090023651A (ko) 2009-03-05
AU2007264946A1 (en) 2008-01-03
CY2020038I2 (el) 2021-03-12
CN101479245A (zh) 2009-07-08
WO2008000839A1 (en) 2008-01-03
CY2020041I2 (el) 2021-03-12
CA2654801C (en) 2014-08-19

Similar Documents

Publication Publication Date Title
BRPI0715712A2 (pt) Composição farmacêutica
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
LTPA2020538I1 (lt) Chinolinonų dariniai ir jų farmacinės kompozicijos
BRPI0719393A2 (pt) Composição farmacêutica
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
PL1861387T3 (pl) Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
BRPI0716445A2 (pt) composiÇço farmacÊutica
NO20092104L (no) Nye 1,2-dihydroquinolinderivater, farmasøytisk sammensetning inneholdende slike, samt anvendelse derav
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
PT1861387E (pt) Derivados de benzimidazol e composições farmacêuticas dos mesmos
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
DK2001891T3 (da) Buprenorfinderivater samt anvendelser deraf
ATE499368T1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
IS2385B (is) Klópidógrel bísúlfat lyfjasamsetningar
BRPI0821455A2 (pt) Composições farmacêuticas de amlopidina e valsartan
BRPI0819202A2 (pt) Derivado heterocíclico, e, composição farmacêutica
DK2001445T3 (da) Farmaceutiske sfæroider
DK2231603T3 (da) Substituerede 3-hydroxypyridiner og farmaceutiske sammensætninger deraf
GB0701295D0 (en) Z-stilbenes derivatives and the pharmaceutical composition thereof